USPTO serial 99078272
DIMDNA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- LOVELACE, JAMES B
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with DIMDNA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
South San Francisco, CA, US
South San Francisco, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Dustin Luettgen
Dustin Luettgen SonoThera, Inc.201 Haskins Way5th FloorSouth San Francisco, CA 94080Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations, enzymes and DNA for the preparation of nucleic acids for scientific and industrial purposes; chemicals for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; linear nucleic acids for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; single stranded nucleic acids for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; single and double-stranded nucleic acids for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; aptamers for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; enzymes for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; DNA extracts and cassettes for scientific, industrial, and research use; DNA extracts being active chemical ingredients for use in the manufacture of therapeutics, biotechnology products and nanotechnology products; chemical preparations in the nature of DNA extracts for use in therapeutic, biotechnology and nanotechnology research | ACTIVE | — |
| 005 | Pharmaceutical preparations for the diagnosis and treatment of human and veterinary genetics disease and genetic diseases treatable with a nucleic acid therapy; pharmaceutical preparations for the prevention and treatment of genetic diseases; pharmaceutical preparations for human genetic medicines for treatment of genetic disease and genetic diseases treatable with a nucleic acid therapy; pharmaceutical preparations consisting of nucleic acid sequences, DNA extracts, and chemical reagents for medical use for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; therapeutic nucleic acid preparations for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; nucleic acid preparations having aptamers for medical or veterinary purposes; pharmaceutical preparations consisting of single stranded nucleic acids, DNA extracts and cassettes for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; pharmaceutical preparations consisting of single and double-stranded nucleic acids, DNA extracts and cassettes for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; pharmaceutical preparations consisting of linear nucleic acids, DNA extracts and cassettes for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; pharmaceutical preparations consisting of single and double-stranded nucleic acids, DNA extracts and cassettes for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; nucleic acid sequences and chemical reagents for medical and veterinary purposes; nucleic acids comprising natural and unnatural nucleotides for medical and veterinary purposes; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for medical and veterinary purposes; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in labeling, imaging and sensing applications; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in smart materials; two-dimensional and three-dimensional nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in creating nanostructures and scaffolds | ACTIVE | — |
| 042 | Scientific and technological services, namely, research and design in the field of nucleic acid research and development; chemical and biological analysis and research services; scientific research in the field of nucleic acids; scientific research and development in the field of creation of DNA extracts; scientific research, analysis, design and development relating to DNA based pharmaceutical drugs and therapies; scientific research and development in the fields of therapeutics, gene therapy, genetic medicines, diagnostics, biotechnology and nanotechnology; scientific research consultancy in the fields of therapeutics, gene therapy, genetic medicines, diagnostics, biotechnology, nanotechnology and DNA analysis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SonoThera, Inc.
- Other trademarks owned by SonoThera, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named DIMDNA
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 5, 2026 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 5, 2026 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 3, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 6, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 6, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 31, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 9, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 9, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 9, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 9, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 9, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 11, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 11, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 11, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 14, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 14, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 14, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 12, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 11, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 11, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 11, 2025 | NWAP | NEW APPLICATION ENTERED | — |